Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | TOP1 | P11387 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316246 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL33584 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL1369560 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3130561 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3128140 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL342904 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Ammonia Solution, Strong SCHEMBL16720911 | 0.98 | LMNA (0.44) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL8675811 | 0.98 | TDP1 (0.48) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Acetic Acid SCHEMBL680584 | 0.94 | PDE4A (0.44) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL616881 | 0.94 | LMNA (0.42) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3271453-B1 | GLYCOSYLATED LYSOSOMAL PROTEINS, METHOD OF PRODUCTION AND USES | eleva GmbH (DE) | 2021-09-08 | — | — | EP | claimed |
| EP-4305698-B1 | POLYSACCHARIDE ELECTROLYTES | FUNDACION CENTRO DE INVESTIG COOPERATIVA DE ENERGIAS ALTERNATIVAS CIC ENERGIGUNE FUNDAZIOA (ES) | 2024-12-18 | — | — | EP | disclosed |
| US-20240162532-A1 | POLYSACCHARIDE ELECTROLYTES | FUNDACION CENTRO DE INVESTIG COOPERATIVA DE ENERGIAS ALTERNATIVAS CIC ENERGIGUNE FUNDAZIOA (ES) | 2024-05-16 | — | — | US | disclosed |
| EP-4305698-A1 | POLYSACCHARIDE ELECTROLYTES | Fundación Centro de Investigación Cooperativa de Energías Alternativas, CIC Energigune Fundazioa (ES) | 2024-01-17 | — | — | EP | disclosed |
| CN-117121244-A | Polysaccharide electrolyte | 可替代能源CIC研究合作中心基金会 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022189566-A1 | POLYSACCHARIDE ELECTROLYTES | FUNDACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA DE ENERGÍAS ALTERNATIVAS CIC ENERGIGUNE FUNDAZIOA (ES) | 2022-09-15 | — | — | WO | disclosed |
| EP-4021510-A2 | CONJUGATES AND CONJUGATES FOR USE IN PREVENTING OR TREATING OF BRAIN DAMAGE AND NEURODEGENERATIVE DISEASES | Medicortex Finland Oy (FI) | 2022-07-06 | — | — | EP | disclosed |
| US-20220120761-A1 | Urine metabolomics based method of detecting renal allograft injury | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | US | disclosed |
| WO-2021038125-A2 | CONJUGATES AND CONJUGATES FOR USE IN PREVENTING OR TREATING OF BRAIN DAMAGE AND NEURODEGENERATIVE DISEASES | MEDICORTEX FINLAND OY (FI) | 2021-03-04 | — | — | WO | disclosed |
| US-20200390774-A1 | TRPA1 ANTAGONISTS FOR USE IN THE TREATMENT OF ATOPIC DERMATITIS | GALDERMA RES & DEV (FR) | 2020-12-17 | — | — | US | disclosed |
| EP-2017289-A1 | PHARMACEUTICAL COMPOSITION FOR CONFORMATIONAL DISEASE | Itoham Foods Inc. (JP) | 2009-01-21 | — | — | EP | disclosed |
| CN-1284845-C | Method for producing liquid biological energy sources by using monosaccharide, oligosaccharide and sugar alcohol | UNIV JINAN (CN) | 2006-11-15 | — | — | CN | disclosed |
| US-7049301-B2 | Quercetin derivatives and their medical usages | ACADEMY OF MILITARY MEDICAL SCIENCES INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY (CN) | 2006-05-23 | — | — | US | disclosed |
| CN-1687323-A | Method for producing liquid biological energy sources by using monosaccharide, oligosaccharide and sugar alcohol | UNIV JINAN (CN) | 2005-10-26 | — | — | CN | disclosed |
| US-20040132671-A1 | Quercetin derivatives and their medical usages | ACADEMY OF MILITARY MEDICAL SCIENCES INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY | 2004-07-08 | — | — | US | disclosed |
| EP-0304183-B1 | Stabilization of deferoxamine to chelate free ions in physiological fluid | BIOMED FRONTIERS INC (US) | 1994-06-08 | — | — | EP | disclosed |
| CN-1084057-A | The local Antipers pirant compositions that mainly contains non-toxicity, water-fast, occlusive film-forming antiperspirant polymer | INT RESEARCH & DEV CO LTD (US) | 1994-03-23 | — | — | CN | disclosed |
| US-5217998-A | Conjugate of deferoxamine covalently joined to a polysaccharide for use in binding ferric or aluminum ions in body fluids | BIOMEDICAL FRONTIERS, INC. (US) | 1993-06-08 | — | — | US | disclosed |
| US-4863964-A | INHIBITING CELL DAMAGE FROM OXIDATION-REDUCTION REACTIONS | BIOMEDICAL FRONTIERS, INC. (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0304183-A1 | Stabilization of deferoxamine to chelate free ions in physiological fluid | BIOMEDICAL FRONTIERS, INC. (US) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132671-A1 | Quercetin derivatives and their medical usages | HTR1A, HTR2A, HTR5A | LMNA 1673/4885L3MBTL1 2464/4885TDP1 447/4885 |
| US-20200390774-A1 | TRPA1 ANTAGONISTS FOR USE IN THE TREATMENT OF ATOPIC DERMATITIS | TRPA1, TRPV1, TRPV2 | LMNA 3982/4885L3MBTL1 4259/4885TDP1 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.